Table 2.
Prior treatment exposure
| Prior treatment regimen | Cohort 1 (n = 13) | Cohort 2 (n = 18) | Cohort 3 (n = 18) | Cohort 4 (n = 43) | Overall (N = 92) |
|---|---|---|---|---|---|
| Median prior treatments – n (range) | 3 (2–10) | 4 (2–11) | 3 (2–14) | 4 (2–10) | 3.5 (2–14) |
| Akylator – n (%) | 13 (100) | 17 (94) | 14 (78) | 40 (93) | 84 (91) |
| Refractory | 6 (46) | 10 (56) | 7 (39) | 17 (40) | 40 (43) |
| Thalidomide – n (%) | 3 (23) | 9 (50) | 11 (61) | 25 (58) | 48 (52) |
| Refractory | 1 (8) | 5 (28) | 5 (28) | 6 (14) | 17 (18) |
| Lenalidomide – n (%) | 13 (100) | 18 (100) | 16 (89) | 39 (91) | 86 (93) |
| Refractory | 9 (69) | 14 (78) | 9 (50) | 27 (63) | 59 (64) |
| Pomalidomide – n (%) | 1 (8) | 1 (6) | 3 (17) | 13 (30) | 18 (20) |
| Refractory | 1 (8) | 0 (0) | 3 (17) | 12 (28) | 16 (17) |
| Bortezomib – n (%) | 13 (100) | 18 (100) | 15 (83) | 39 (91) | 85 (92) |
| Refractory | 6 (46) | 14 (78) | 10 (56) | 22 (51) | 52 (57) |
| Carfilzomib – n (%) | 1 (8) | 5 (28) | 6 (33) | 14 (33) | 26 (28) |
| Refractory | 0 (0) | 5 (28) | 6 (33) | 12 (28) | 23 (25) |
| Monoclonal antibody – n (%) | 1 (8) | 4 (22) | 2 (11) | 4 (9) | 12 (13) |
| Elotuzumab | 0 (0) | 2 (11) | 1 (6) | 0 (0) | 3 (3) |
| Othera | 1 (8) | 2 (11) | 1 (6) | 5 (12) | 9 (10) |
| Autologous stem cell transplant – n (%) | 11 (85) | 14 (78) | 13 (72) | 33 (77) | 71 (77) |
| PI and IMiD – n (%) | 13 (100) | 18 (100) | 15 (83) | 40 (93) | 86 (93) |
IMiD, immunomodulatory agent; PI, proteasome inhibitor.
a
Other includes investigational (BB‐1091, BHQ880, BMS‐936564, BT062; n = 4), rituximab (n = 2), nivolumab (n = 1), tositumomab (n = 1), and SAR650984 (n = 1).